{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:50:07Z","timestamp":1780638607255,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T00:00:00Z","timestamp":1372809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2288-13-87","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T08:14:14Z","timestamp":1372839254000},"source":"Crossref","is-referenced-by-count":11,"title":["Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia"],"prefix":"10.1186","volume":"13","author":[{"given":"Christina","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"key":"971_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, et al: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 Trial. J Clin Oncol. 2012, 30: 1647-1655. 10.1200\/JCO.2011.35.9695.","journal-title":"J Clin Oncol"},{"key":"971_CR2","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008, 111: 5446-5456. 10.1182\/blood-2007-06-093906.","journal-title":"Blood"},{"key":"971_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989, 10: 1-10. 10.1016\/0197-2456(89)90015-9.","journal-title":"Control Clin Trials"},{"key":"971_CR4","first-page":"1375","volume":"69","author":"R Simon","year":"1985","unstructured":"Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep. 1985, 69: 1375-1381.","journal-title":"Cancer Treat Rep"},{"key":"971_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/10543400902802391","volume":"19","author":"SH Jung","year":"2009","unstructured":"Jung SH, George SL: Between-arm comparisons in randomized phase II trials. J Biopharma Stat. 2009, 19: 456-468. 10.1080\/10543400902802391.","journal-title":"J Biopharma Stat"},{"key":"971_CR6","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","volume":"23","author":"LV Rubinstein","year":"2005","unstructured":"Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005, 23: 7199-7206. 10.1200\/JCO.2005.01.149.","journal-title":"J Clin Oncol"},{"key":"971_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1182\/blood-2002-09-2937","volume":"102","author":"EH Estey","year":"2003","unstructured":"Estey EH, Thall PF: New designs for phase 2 clinical trials. Blood. 2003, 102: 442-448. 10.1182\/blood-2002-09-2937.","journal-title":"Blood"},{"key":"971_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/biomet\/75.2.303","volume":"75","author":"PF Thall","year":"1988","unstructured":"Thall PF, Simon R, Ellenberg SS: 2-stage selection and testing designs for comparative clinical-trials. Biometrika. 1988, 75: 303-310. 10.1093\/biomet\/75.2.303.","journal-title":"Biometrika"},{"key":"971_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0197-2456(99)00009-4","volume":"20","author":"PY Liu","year":"1999","unstructured":"Liu PY, LeBlanc M, Desai M: False positive rates of randomized phase II designs. Control Clin Trials. 1999, 20: 343-352. 10.1016\/S0197-2456(99)00009-4.","journal-title":"Control Clin Trials"},{"key":"971_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/sim.704","volume":"20","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Goldberg RM: A flexible design for multiple armed screening trials. Stat Med. 2001, 20: 1051-1060. 10.1002\/sim.704.","journal-title":"Stat Med"},{"key":"971_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung SH, Lee T, Kim K, George SL: Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004, 23: 561-569. 10.1002\/sim.1600.","journal-title":"Stat Med"},{"key":"971_CR12","volume-title":"Multc Lean Statistical Tutorial","author":"J Cook","year":"2005","unstructured":"Cook J: Multc Lean Statistical Tutorial. 2005, USA: Department of Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center"},{"key":"971_CR13","volume-title":"clinfun: Clinical Trial Design and Data Analysis Functions. (R package version 1.0.3.)","author":"VE Seshan","year":"2012","unstructured":"Seshan VE: clinfun: Clinical Trial Design and Data Analysis Functions. (R package version 1.0.3.). 2012, \n                    http:\/\/CRAN.R-project.org\/package=clinfun\n                    \n                  ,"},{"key":"971_CR14","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1","volume":"16","author":"TT Chen","year":"1997","unstructured":"Chen TT: Optimal three-stage designs for phase II cancer clinical tribes. Stat Med. 1997, 16: 2701-2711. 10.1002\/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1.","journal-title":"Stat Med"},{"key":"971_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1201\/b11800-13","volume-title":"Handbook of Statistics in Clinical Oncology. Third edition","author":"PY Liu","year":"2012","unstructured":"Liu PY, Moon J, LeBlanc M: Phase II selection designs. Handbook of Statistics in Clinical Oncology. Third edition. Edited by: Crowley J, Hoering A. 2012, Chapman & Hall\/CRC, 151-161."},{"key":"971_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2288-3-6","volume":"3","author":"L Case","year":"2003","unstructured":"Case L, Morgan T: Design of phase II cancer trials evaluating survival probabilities. BMC Med Res Methodol. 2003, 3: 6-10.1186\/1471-2288-3-6.","journal-title":"BMC Med Res Methodol"},{"key":"971_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2307\/2532552","volume":"49","author":"PY Liu","year":"1993","unstructured":"Liu PY, Dahlberg S, Crowley J: Selection designs for pilot-studies based on survival. Biometrics. 1993, 49: 391-398. 10.2307\/2532552.","journal-title":"Biometrics"},{"key":"971_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2307\/2533268","volume":"51","author":"J Bryant","year":"1995","unstructured":"Bryant J, Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995, 51: 1372-1383. 10.2307\/2533268.","journal-title":"Biometrics"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2288-13-87\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-13-87.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-13-87","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-13-87.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T19:35:15Z","timestamp":1548099315000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-13-87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1186\/1471-2288-13-87","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,3]]},"article-number":"87"}}